Vitamin D Supplementation As a Potential therapeutic Mediator in Asthma: Does Dose Really Matter? a Critical Review of the Literature.
Önder CangüvenWelid El AnsariAksam YassinPublished in: The aging male : the official journal of the International Society for the Study of the Aging Male (2018)
Around 400 million people across the globe will suffer from asthma in the next 10 years. Although most asthmatics use asthma medications regularly, they occasionally visit the emergency department for aggressive treatment amidst family anxiousness. Vitamin D (VD) not only regulates the expression of genes associated with calcium homeostasis, but also the genes associated with cancers, autoimmune diseases, and infection. VD has also non-genomic activities e.g. it is a potentially safe and effective novel strategy for decreasing the asthma episodes and controlling exacerbations. Our review assessed the dose, serum level, duration of administration and outcomes of VD in cases of asthmas. Although a body of research evidences the effectiveness of VD supplementation in asthma, other studies showed the insignificant response of VD to asthma either with low dose or low achieved serum VD levels. Nevertheless, recent reviews suggest that manipulating VD status holds promise for primary prevention and treatment of asthma. Future research on the relationship between VD and asthma should consider utilizing adequate doses of VD preparations for sufficient duration (likely to be >12 months) aiming to achieve appropriate level of serum VD (25-hydroxyvitamin D) concentration (likely to be at least >40 ng/mL).
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- allergic rhinitis
- emergency department
- low dose
- randomized controlled trial
- systematic review
- poor prognosis
- type diabetes
- adipose tissue
- dna methylation
- current status
- artificial intelligence
- long non coding rna
- copy number
- big data
- combination therapy
- weight loss
- replacement therapy
- adverse drug
- electronic health record